Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

This study has been terminated.
(The study was terminated for business reasons and not due to any safety or efficacy concerns related to omarigliptin)
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: October 5, 2012
Last updated: April 5, 2017
Last verified: April 2017
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: March 22, 2017
  Primary Completion Date: March 22, 2017 (Final data collection date for primary outcome measure)